![Foto de Emilio](/img/nophoto.png)
Emilio
Alba
Publicacións nas que colabora con Emilio Alba (23)
2022
2021
2019
-
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
Scientific Reports, Vol. 9, Núm. 1
2018
-
Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study
European Journal of Cancer, Vol. 94, pp. 199-205
-
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556
2017
-
A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse
Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044
2016
-
High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer
Oncologist, Vol. 21, Núm. 2, pp. 150-155
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2015
-
Defining breast cancer intrinsic subtypes by quantitative receptor expression
Oncologist, Vol. 20, Núm. 5, pp. 474-482
2014
-
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: Results from the GEICAM 9906 trial
Breast Cancer Research, Vol. 16, Núm. 2
-
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541
-
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: Results from the GEICAM/2006-14 trial
British Journal of Cancer, Vol. 110, Núm. 5, pp. 1139-1147
2013
-
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: A pooled analysis
Breast Cancer Research, Vol. 15, Núm. 6
2012
-
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
Breast Cancer Research and Treatment, Vol. 136, Núm. 2, pp. 487-493
-
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: Results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
Annals of Oncology, Vol. 23, Núm. 12, pp. 3069-3074
2011
-
Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer
Breast Cancer Research and Treatment, Vol. 125, Núm. 1, pp. 273-278
2010
-
Adjuvant docetaxel for high-risk, node-negative breast cancer
New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210
-
Current controversies in the management of breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286
-
Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))
Clinical and Translational Oncology
-
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer
Breast Cancer Research and Treatment, Vol. 123, Núm. 1, pp. 149-157